Finance

Lists
1AE:ETR
argenx SE
€887,20
+1,21%
(+10,60) 1D
1 Sep., 17:35:40 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1AE...
Open
€879,20
High
€891,40
Low
€879,20
Mkt. cap
55,55 mjd
Avg. vol.
260,00
Volume
130,00
P/E ratio
39,05
52-wk high
€909,20
52-wk low
€574,20
EPS
€22,72
No. of employees
2 k
Open
€879,20
High
€891,40
Low
€879,20
Mkt. cap
55,55 mjd
Avg. vol.
260,00
Volume
130,00
P/E ratio
39,05
52-wk high
€909,20
52-wk low
€574,20
EPS
€22,72
No. of employees
2 k
News stories
From web sources and news partners
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE
CEO-
Employees1,86 k
Founded2008
Headquarters-
Sector-
Websiteargenx.com
Last report
23 Jul. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 7,32 / USD 6,19
+18,17%beat
Revenue / Est. (USD)
1,54 mjd / 1,44 mjd
+6,82%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,15 mjd
1,31 mjd
1,31 mjd
1,54 mjd
Cost of goods sold
465,08 m
521,40 m
564,00 m
631,00 m
Cost of revenue
465,08 m
521,40 m
564,00 m
631,00 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
336,29 m
429,62 m
355,00 m
417,00 m
Operating expense
336,29 m
429,62 m
355,00 m
417,00 m
Total operating expenses
801,37 m
951,02 m
919,00 m
1,05 mjd
Operating income
349,97 m
359,56 m
394,00 m
493,00 m
Other non operating income
-
-907,00 k
-
-1,00 m
EBT including unusual items
386,05 m
403,29 m
426,00 m
531,00 m
EBT excluding unusual items
386,05 m
391,71 m
426,00 m
531,00 m
Income tax expense
41,80 m
-129,66 m
60,00 m
59,00 m
Effective tax rate
10,83%
-32,15%
14,08%
11,11%
Other operating expenses
-
-
-
-
Net income
344,26 m
532,95 m
366,00 m
472,00 m
Net profit margin
29,90%
40,67%
27,88%
30,63%
Earnings per share
5,18
8,02
5,52
7,32
Interest and investment income
42,70 m
44,95 m
44,00 m
48,00 m
Interest expense
-993,00 k
-
-1,00 m
-1,00 m
Net interest expenses
41,71 m
44,95 m
43,00 m
47,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
350,35 m
361,38 m
395,82 m
501,50 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme